<DOC>
	<DOCNO>NCT00765063</DOCNO>
	<brief_summary>The primary objective 6 month open-label extension trial evaluate long-term safety tolerability dalteparin treatment chronic neuroischaemic foot ulcer diabetic patient peripheral arterial occlusive disease ( PAOD ) peripheral neuropathy .</brief_summary>
	<brief_title>The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients ( A6301086 )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Subjects must complete 6 month study duration A6301083 study . Subjects must positive ulcer treatment response , define reduction study ulcer area size ( ie , ulcer area reduction &gt; 0 % ) Visit 8 ( EOT Visit ) baseline A6301083 study . All ulcer must ulcer stag 1C , 2C , 1D 2D accord University Texas wound classification system Subjects follow : Intact skin healing ( defined 100 % reduction ulcer surface area full epithelialisation prior EOT visit A6301083 study ) . A study ulcer area Visit 8 ( EOT visit ) great equal baseline ulcer area ( ie , ulcer area increase â‰¥0 % ) A6301083 study . Subjects ulcer grade 0 3 stag A B accord University Texas wound classification system . Subjects know bleed disorder evidence active bleeding . Subjects dialysis . Subjects found major protocol violator A6301083 study . Subjects complete 6 month study period A6301083 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Diabetic Foot Ulcers Neuroischaemic</keyword>
</DOC>